Epigenetic inactivation of DNA repair in breast cancer

Cancer Lett. 2014 Jan 28;342(2):213-22. doi: 10.1016/j.canlet.2012.05.015. Epub 2012 May 23.

Abstract

The study of epigenetic mechanisms in cancer, such as DNA methylation and histone modifications, has revealed a plethora of events that contribute to cancer through stable changes in the expression of genes critical to transformation pathways. In this mini review we look at the different epigenetic modifications prevalent in this neoplastic phenotype, focusing on breast cancer. Most encouragingly, research in epigenetics has led to improved survival of patients with certain forms of lymphoma and leukemia through the use of drugs that alter DNA methylation and histone acetylation. Thus, we look at the clinical utility of targeting epigenetic pathways. In addition, we explore numerous other clinical applications of epigenetics, in areas such as cancer screening and early detection, prevention, classification for epidemiology and prognostic purposes, and predicting outcomes after standard therapy.

Keywords: Biomarkers; Breast cancer; Cancer; Carcinogenesis; DNA damage; Epigenetics; Personalized treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • DNA Damage
  • DNA Methylation
  • DNA Repair*
  • Epigenesis, Genetic*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Genetic Predisposition to Disease
  • Genetic Testing
  • Histones / metabolism
  • Humans
  • MicroRNAs / metabolism
  • Molecular Targeted Therapy
  • Phenotype
  • Precision Medicine
  • Predictive Value of Tests
  • Prognosis

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Histones
  • MicroRNAs